These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 3156026

  • 21. In vitro activity of the newer quinolones compared with the classic ones and tobramycin.
    Boquet Jiménez E, Dalet Escribá F, Caballé L.
    Infection; 1985; 13(4):193-6. PubMed ID: 2931382
    [Abstract] [Full Text] [Related]

  • 22. Cross resistance of quinolone derivatives in gram-negative bacteria.
    Barba D, Pennucci C, Esposito S, Galante D.
    Chemioterapia; 1985 Apr; 4(2):192-6. PubMed ID: 3159488
    [Abstract] [Full Text] [Related]

  • 23. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL, Thornsberry C, Jones RN.
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [Abstract] [Full Text] [Related]

  • 24. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
    Ridgway GL, O'Hare MD, Felmingham D, Grüneberg RN.
    Drugs Exp Clin Res; 1985 Jan; 11(4):259-62. PubMed ID: 2941258
    [Abstract] [Full Text] [Related]

  • 25. Nalidixic acid analogues and Shigella.
    Bannatyne RM, Toma S, Cheung R.
    Lancet; 1984 Jul 21; 2(8395):172-3. PubMed ID: 6146075
    [No Abstract] [Full Text] [Related]

  • 26. Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
    Nakamura S, Nakata K, Katae H, Minami A, Kashimoto S, Yamagishi J, Takase Y, Shimizu M.
    Antimicrob Agents Chemother; 1983 May 21; 23(5):742-9. PubMed ID: 6223579
    [Abstract] [Full Text] [Related]

  • 27. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1984 Apr 21; 13(4):325-31. PubMed ID: 6233249
    [Abstract] [Full Text] [Related]

  • 28. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H.
    Infection; 1986 Apr 21; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [Abstract] [Full Text] [Related]

  • 29. Ciprofloxacin (BAY O 9867). Comparative in vitro activity study.
    Canton E, Garcia J, Vila B, Santos M, Gobernado M.
    Microbiol Esp; 1984 Apr 21; 37(3-4):73-9. PubMed ID: 6242123
    [No Abstract] [Full Text] [Related]

  • 30. The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.
    Greenwood D.
    J Antimicrob Chemother; 1984 May 21; 13 Suppl B():43-8. PubMed ID: 6234274
    [Abstract] [Full Text] [Related]

  • 31. [Evaluation of the in vitro activity of enoxacin on bacterial strains recently isolated in a hospital milieu].
    Lembo M, Nani E, Covelli I, Amato G, Lavitola A.
    G Batteriol Virol Immunol; 1985 May 21; 78(7-12):205-16. PubMed ID: 3870425
    [Abstract] [Full Text] [Related]

  • 32. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.
    Duckworth GJ, Williams JD.
    J Antimicrob Chemother; 1984 May 21; 13 Suppl B():33-8. PubMed ID: 6234273
    [Abstract] [Full Text] [Related]

  • 33. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD, Felmingham D, Ridgway GL, Grüneberg RN.
    Drugs Exp Clin Res; 1985 May 21; 11(4):253-7. PubMed ID: 2941257
    [Abstract] [Full Text] [Related]

  • 34. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N.
    Eur J Clin Microbiol; 1986 Apr 21; 5(2):138-40. PubMed ID: 3013628
    [No Abstract] [Full Text] [Related]

  • 35. Comparative in vitro activity of ciprofloxacin and five other quinoline derivatives against gram-negative isolates.
    Galante D, Pennucci C, Esposito S, Barba D.
    Drugs Exp Clin Res; 1985 Apr 21; 11(5):331-4. PubMed ID: 2941260
    [Abstract] [Full Text] [Related]

  • 36. Nonspecific resistance of Serratia marcescens against antimicrobial drugs. Resistance or decreased susceptibility of phenotypic variants against chloramphenicol, nalidixic acid, nitrofurantoin, sulfonamides and trimethoprim.
    Traub WH, Fukushima PI.
    Chemotherapy; 1979 Apr 21; 25(4):196-203. PubMed ID: 378575
    [Abstract] [Full Text] [Related]

  • 37. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P.
    Infection; 1986 Apr 21; 14(3):142-4. PubMed ID: 2942489
    [Abstract] [Full Text] [Related]

  • 38. In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid.
    Shah PM, Ottrad M, Stille W.
    Eur J Clin Microbiol; 1983 Jun 21; 2(3):272-4. PubMed ID: 6224688
    [No Abstract] [Full Text] [Related]

  • 39. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM, Zemcov SJ, Campbell ME.
    J Antimicrob Chemother; 1985 Jan 21; 15(1):39-44. PubMed ID: 3156112
    [Abstract] [Full Text] [Related]

  • 40. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG, Sörgel F, Gutzler F, Bartosik-Wich B.
    Infection; 1985 Jan 21; 13(5):219-24. PubMed ID: 2933340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.